Cart 2
  • Anti-C4.4A/LYPD3 antibody

Anti-C4.4A/LYPD3 antibody

Cat.#: 103646

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-C4.4A/LYPD3 antibody
  • Documents
  • Description
    Rabbit polyclonal to C4.4A/LYPD3
  • Tested applications
  • Species reactivity
    Human C4.4A / LYPD3
  • Alternative names
    C4.4A antibody; C4.4a antibody; 2310061G07Rik antibody; C4.4a antibody; LYPD3 antibody; UNQ491/PRO1007 antibody; 2310061G07Rik antibody; C4.4A antibody; Lypd3 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    Produced in rabbits immunized with purified, recombinant Human C4.4A / LYPD3 (rh C4.4A / LYPD3; NP_055215.2; Met 1-His 286). C4.4A / LYPD3 specific IgG was purified by Human C4.4A / LYPD3 affinity chromatography.
  • Clonality
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    ELISA: 0.1-0.2 μg/mL

    This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human LYPD3. The detection limit for Human LYPD3 is approximately 0.00245 ng/well.

  • Validations
  • Background
    Ly6 / PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4 and LYPD3, is a cell membrane protein which contains two UPAR/Ly6 domains. Human LYPD3 contains two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression
  • References
    • Smith B.A., et al., 2001, Cancer Res. 61:1678-85.
    • Wuerfel J., et al., 2001, Gene 262:35-41.
    • Clark H.F., et al., 2003, Genome Res. 13:2265-70.
    • Fletcher G.C., et al., 2003, Br. J. Cancer 88:579-85.
    • Hansen L.V., et al., 2004, Biochem. Eng. J. 380:845-57.